MV Capital Management Inc. Boosts Holdings in Kenvue Inc. (NYSE:KVUE)

MV Capital Management Inc. lifted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 71.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,544 shares of the company’s stock after buying an additional 642 shares during the quarter. MV Capital Management Inc.’s holdings in Kenvue were worth $33,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Planned Solutions Inc. purchased a new position in shares of Kenvue during the fourth quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Kenvue during the fourth quarter valued at about $28,000. Mather Group LLC. purchased a new position in shares of Kenvue during the first quarter valued at about $28,000. CVA Family Office LLC purchased a new position in shares of Kenvue during the fourth quarter valued at about $32,000. Finally, Pinnacle Bancorp Inc. increased its position in shares of Kenvue by 51.3% during the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company’s stock valued at $33,000 after buying an additional 526 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several research analyst reports. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. HSBC increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Finally, Citigroup reaffirmed a “neutral” rating and set a $21.00 price target on shares of Kenvue in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus price target of $23.09.

Kenvue Price Performance

Kenvue stock opened at $18.24 on Wednesday. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $26.60. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $19.14 and a 200-day moving average price of $19.93. The firm has a market capitalization of $34.93 billion, a PE ratio of 23.38, a price-to-earnings-growth ratio of 1.93 and a beta of 1.41.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.03. The business had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The business’s revenue was down 24.9% on a year-over-year basis. As a group, equities research analysts forecast that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were paid a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.39%. Kenvue’s payout ratio is 102.56%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.